The UCLA Division of Pediatric Hematology/Oncology is a pioneer in the treatment of childhood cancers at Mattel Children’s Hospital UCLA. The Pediatric Hematology Oncology faculty actively participate in the Jonsson Comprehensive Cancer Center, well-known for its new and leading-edge therapies and research breakthroughs. The Division has a long history of bringing hope to patients through programs that include the Bone Marrow Transplant Unit, in continuous operation since 1973, which is the oldest such unit in California and one of the first in the nation.
The annual Dribble for the Cure event helps to support the Pediatric Cancer Program at Mattel Children’s Hospital UCLA, as it pursues innovative ways to treat and cure childhood cancers. The clinical and research programs help patients and their families by providing the finest care and translating discoveries in the lab into effective treatment options. For example, UCLA’s physician-scientists are seeking novel methods to improve survival rates and to decrease complications in young patients undergoing bone-marrow transplantations. Other research efforts include the use of cellular and gene therapies, nanotechnology and stem cell biology to bring cures to children with cancer. Our programs in cancer survivorship and the Daltrey Townshend Teen and Young Adult Cancer Zone serve to significantly and positively improve the quality of life and quality of care for children and young people with cancer. Our outreach efforts connect people throughout the Southern California region to our providers and the quaternary care available at UCLA Health. We are proud to announce the opening of our services in pediatric hematology oncology at Miller Children’s Hospital in Long Beach.
A hallmark of the research program is the proximity of the health sciences enterprise to the wealth of research resources on the UCLA campus. The UCLA Division of Pediatric Hematology/Oncology within the David Geffen School of Medicine is adjacent to the Broad Stem Cell and Regenerative Medicine Research Center, the California nanoSystems Institute, the Terasaki Life Sciences Center, the Henry Samueli School of Engineering and Applied Sciences, the Schools of Dentistry, Nursing and Public Health among others. This close proximity allows physicians and scientists in basic, translational and clinical research to collaborate on many projects. This multidisciplinary approach has forged traditional therapies with discoveries in bioengineering and nanotechnology leading to better understanding and treatment of pediatric cancer and other diseases.
Some people say that children make up 10% of our cancer population, but they are 100% of our future! ~ Dr. Alex Huang, Case Western